drugset / Trial / NCT00532077

A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

NCT00532077

Phase 1 Completed 40 enrolled GlaxoSmithKline
RandomizedSingle-groupOpen-labelTreatment

Summary

SB-751689 may alter calcium and phosphate handling at the kidney level. This study will examine what happens to calcium and phosphate, and other electrolytes, at the kidney after treatment with SB-751689 for 1 month. Another group of subjects will get another drug called Forteo for 1 month to compare the response of the kidney for calcium and phosphate.

Timeline

Start
2007-08
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SB-751689 Unknown 100 mg
Subject SB-751689 Unknown 400 mg
Subject Teriparatide Protein / enzyme biologic

Indications